Endothelin-1-induced vasopressor responses in essential hypertension

Hypertension

Volumn 30, Issue 1, 1997, Pages 15-21

  Kaasjager, Karin A H ^b   Koomans, Hein A ^b   Rabelink, Ton J ^a  

^a UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^b NONE

Author keywords

Angiotensin converting enzyme inhibitors; Calcium channel blockers; Endothelin; Hypertension essential

Indexed keywords

CALCIUM CHANNEL BLOCKING AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ENALAPRIL; NIFEDIPINE;

ANTIHYPERTENSIVE ACTIVITY; ANTIHYPERTENSIVE THERAPY; ARTICLE; BLOOD VESSEL REACTIVITY; CLINICAL ARTICLE; DRUG EFFECT; ESSENTIAL HYPERTENSION; HUMAN; KIDNEY BLOOD FLOW; PATHOPHYSIOLOGY; PRIORITY JOURNAL;

EID: 0030745782     PISSN: 0194911X     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.HYP.30.1.15     Document Type: Article

References (45)

1. Kiowski W, Lüscher TF, Under L, Bühler FR. Endothelin-1-induced vasoconstriction in humans: reversal by calcium channel blockade but not by nitrovasodilators or endothelium-derived relaxing factor. Circulation. 1991;83:469-475.
2. Haynes WG, Webb DJ. Contribution of endogenous generation of endothelin-1 to basal vascular tone. Lancet. 1994;344:852-854.
3. Rabelink TJ, Kaasjager HAH, Boer P, Stroes EG, Braam B, Koomans HA. Effects of endothelin-1 on renal function in humans: implications for physiology and pathophysiology. Kidney Int. 1994; 46:376-381.
4. Bobik A, Grooms A, Millar JA, Mitchell A, Grinpukel S. Growth factor activity of endothelin on vascular smooth muscle. Am J Physiol. 1990;258:C408-C415.
5. Li JS, Larivière R, Schiffrin EL. Effect of a nonselective endothelin antagonist on vascular remodeling in DOCA-salt hypertensive rats. Hypertension. 1994;24:183-188.
6. Rabelink TJ, Kaasjager KAH, Stroes ESG, Koomans HA. Endothelin in renal medicine: from pathophysiology to therapy. Kidney Int. 1996;50:1827-1832.
7. Florijn KW, Derkx FHM, Visser W, Hofman HJA, Rosmalen FMA, Wallenburg HCS, Schalekamp MADH. Elevated plasma levels of endothelin in pre-eclampsia. J Hypertens. 1991;9: S166-S167.
8. Stockenhuber F, Gottsauner-Wolf M, Marosi L, Liebisch B, Kurz RW, Balcke P. Plasma levels of endothelin in chronic renal failure and after renal transplantation: impact on hypertension and cyclosporin A-associated nephrotoxicity. Clin Sci. 1991;82:255-258.
9. Shichiri M, Hirata Y, Ando K, Emori T, Ohta K, Kimoto S, Ogura M, Inoue A, Marumo F. Plasma endothelin levels in hypertension and chronic renal failure. Hypertension. 1990;15:493-496.
10. Day R, Larivière R, Schiffrin EL. In situ hybridization shows increased endothelin-1 mRNA levels in endothelial cells of blood vessels of deoxycorticosterone acetate-salt hypertensive rats. Am J Hypertens. 1995;8:294-300.
11. Larivière R, Day R, Schiffrin EL. Increased expression of endothelin-gene in blood vessels of deoxycorticosterone acetate-salt hypertensive rats. Hypertension. 1993;21:916-920.
12. Schiffrin EL, Deng LY, Sventek P, Day R. Expression of endothelin-1 in small arteries in human essential hypertension. Hypertension. 1996;28:509. Abstract.
13. Larivière R, Sventek P, Schiffrin EL. Expression of endothelin-1 gene in blood vessels of spontaneously hypertensive rats. Life Sci. 1995;56:1889-1896.
14. Larivière R, Thibault G, Schiffrin EL. Increased endothelin-1 content in blood vessels of deoxycorticosterone acetate-salt hypertensive but not in spontaneously hypertensive rats. Hypertension. 1993;21:294-300.
15. Nguyen PV, Yang X-P, Li G, Deng LY, Flückiger J-P, Schiffrin EL. Contractile responses and signal transduction of endothelin-1 in aorta and mesenteric vasculature of adult spontaneously hypertensive rats. Can J Physiol Pharmacol. 1993;71:473-483.
16. Deng LY, Schiffrin EL. Effects of endothelin-1 and vasopressine on small arteries of spontaneously hypertensive rats. Am J Hypertens. 1992;5:817-822.
17. Dohi Y, Lüscher TF. Endothelin in hypertensive small arteries: intraluminal and extraluminal dysfunction. Hypertension. 1991;18: 543-549.
18. Schiffrin EL, Deng LY, Larochelle P. Blunted effects of endothelin on small subcutaneous resistance arteries of mild essential hypertensive patients. J Hypertens. 1992;10:437-444.
19. Schiffrin EL, Deng LY, Larochelle P. Morphology of resistance arteries and comparison of effects of vasoconstrictors in mild essential hypertensive patients. Clin Invest Med. 1993;16:177-186.
20. Yanagisawa M, Kurihara H, Kimura S, Tomobe Y, Kobayashi M, Mitsui Y, Yazaki Y, Goto K, Masaki T. A novel potent vasoconstrictor peptide produced by vascular endothelial cells. Nature. 1988;332:411-415.
21. Dohi Y, Hahn AWA, Boulanger CM, Bühler FR, Lüscher TF. Endothelin stimulated by angiotensin II augments contractility of spontaneously hypertensive rat resistance arteries. Hypertension. 1992;19:131-137.
22. Linder L, Kiowski W, Bühler H, Lüscher TF. Indirect evidence for the release of endothelium-derived relaxing factor in the human forearm circulation in vivo: blunted response in essential hypertension. Circulation. 1990;81:1762-1767.
23. Panza JA, Casino PR, Kilcoyne CM, Quyyumi AA. Role of endothelium-derived nitric oxide in the abnormal endothelium-dependent vascular relaxation of patients with essential hypertension. Circulation. 1993;87:1468-1474.
24. Clozel M. Mechanism of action of angiotensin converting enzyme inhibitors on endothelial function in hypertension. Hypertension. 1991;18:37-42.
25. Waugh WH, Beall PT. Simplified measurement of p-amino-hippurate and other arylamines in plasma and urine. Kidney. 1974; 5:429-436.
26. Heyrowski A. A new method for determination of inulin in plasma and urine. Clin Chim Acta. 1956;1:470-474.
27. Rabelink TJ, Koomans HA, Boer P, Gaillard CA, Dorhout Mees EJ. The role of ANP in the natriuresis of head-out immersion in humans. Am J Physiol. 1989;257:F375-F382.
28. Kaasjager KAH, Koomans KA, Rabelink TJ. Effectiveness of enalapril versus nifedipine to antagonize blood pressure and the renal response to endothelin in humans. Hypertension. 1995;25:620-625.
29. Miller WL, Cavero PG, Aarhus LL, Heublein DM, Burnett JC Jr. Endothelin mediated cardiorenal hemodynamic and neurocrine effects by nitroglycerin in vivo. Am J Hypertens. 1993;6:156-163.
30. Weitzberg E, Ahlborg G, Lundberg JM. Differences in vascular effects and removal of endothelin-1 in human lung, brain, and skeletal muscle. Clin Physiol. 1993;13:653-662.
31. Beyer ME, Nerz S, Kramer BT, Hoffmeister HM. Hemodynamic and inotropic effects of endothelin-1 in vivo. Basic Res Cardiol. 1994;89:39-49.
32. Schiffrin EL. Endothelin: potential role in hypertension and vascular hypertrophy. Hypertension. 1995;25:1135-1143.
33. Kohno M, Murakawa K, Horio T, Yokokawa K, Yasunari K, Fukui T, Takeda T. Plasma immunoreactive endothelin-1 in experimental malignant hypertension. Hypertension. 1991;18:93-100.
34. Fogo A, Hakim RC, Sugiara M, Inagami M, Inagami T, Kon V. Severe endothelial injury in a renal transplant patient receiving cyclosporine. Transplantation. 1990;49:1190-1192.
35. Carlini R, Obialo CI, Rothstein M. Intravenous erythropoietin (rHuEPO) administration increases plasma endothelin and blood pressure in hemodialysis patients. Am J Hypertens. 1993;6:103-107.
36. Clozel M. Endothelin sensitivity and receptor binding in the aorta of spontaneously hypertensive rats. J Hypertens. 1989;17:913-917.
37. Deng LY, Schiffrin EL. Effect of antihypertensive treatment on response to endothelin of resistance arteries of hypertensive rats. J Cardiovasc Pharmacol. 1993;21:725-731.
38. Haynes WG, Hand MF, Johnstone HA, Padfield PL, Webb DJ. Direct and sympathetically mediated venoconstriction in essential hypertension. J Clin Invest. 1994;94:1359-1364.
39. Banks RO. Effects of endothelin on renal function in dogs and rats. Am J Physiol. 1990;258:F775-F780.
40. Hirooka Y, Imaizumi T, Masaki H, Ando S, Harada S, Momohara M, Takeshita A. Captopril improves impaired endothelium-dependent vasodilatation in hypertensive patients. Hypertension. 1992;20:175-180.
41. Bijlsma JA, Rabelink TJ, Kaasjager KAH, Koomans HA. L-Arginine does not prevent the renal effects of endothelin in humans. J Am Soc Nephrol. 1995;5:1508-1517.
42. van der Schaaf MR, Hene RJ, Floor M, Blankenstijn PJ, Koomans HA. Hypertension after renal transplantation. Hypertension. 1995; 25:77-81.
43. Phillips PA, Rolls KA, Burrell LM, Casley D, Aldred KL, Hardy KJ. Vascular endothelin responsiveness and receptor characteristics in vitro and effects of endothelin receptor blockade in vivo in cyclosporin hypertension. Clin Exp Pharmacol Physiol. 1994;21: 223-226.
44. Clavel AL, Stingo AJ, Margulies KB, Brandt RR, Burnett JC Jr. Role of endothelin receptor subtypes in the vivo regulation of renal function. Am J Physiol. 1995;768:F455-F460.
45. MacGregor GA, Pevahouse JB, Cappuccio FP, Markandu ND. Nifedipine, sodium intake, diuretics and sodium balance. Am J Nephrol. 1987;7:44-48.